What happens if too much glucose is administered during hypoglycemia?
|
Show
SummaryRead the full fact sheet
This page has been produced in consultation with and approved by:
This page has been produced in consultation with and approved by: Related information
From other websitesContent disclaimerContent on this website is provided for information purposes only. Information about a therapy, service, product or treatment does not in any way endorse or support such therapy, service, product or treatment and is not intended to replace advice from your doctor or other registered health professional. The information and materials contained on this website are not intended to constitute a comprehensive guide concerning all aspects of the therapy, product or treatment described on the website. All users are urged to always seek advice from a registered health care professional for diagnosis and answers to their medical questions and to ascertain whether the particular therapy, service, product or treatment described on the website is suitable in their circumstances. The State of Victoria and the Department of Health shall not bear any liability for reliance by any user on the materials contained on this website. 1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. [PubMed] [Google Scholar] 2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–53. [PubMed] [Google Scholar] 3. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11–66. [PMC free article] [PubMed] [Google Scholar] 4. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. [PubMed] [Google Scholar] 5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39. [PubMed] [Google Scholar] 6. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. [PMC free article] [PubMed] [Google Scholar] 7. Kim JT, Oh TJ, Lee YA, Bae JH, Kim HJ, Jung HS, et al. Increasing trend in the number of severe hypoglycemia patients in Korea. Diabetes Metab J. 2011;35:166–72. [PMC free article] [PubMed] [Google Scholar] 8. Reichard P, Britz A, Carlsson P, Cars I, Lindblad L, Nilsson BY, et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): The Stockholm Diabetes Intervention Study (SDIS) J Intern Med. 1990;228:511–7. [PubMed] [Google Scholar] 9. Noh RM, Graveling AJ, Frier BM. Medically minimising the impact of hypoglycemia in type 2 diabetes: A review. Expert Opin Pharmacother. 2011;12:2161–75. [PubMed] [Google Scholar] 10. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE-SUGAR study data. Can Med Assoc J. 2009;180:821–7. [PMC free article] [PubMed] [Google Scholar] 11. UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7. [PubMed] [Google Scholar] 12. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: A cross-sectional survey. Diabet Med. 2006;23:750–6. [PubMed] [Google Scholar] 13. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: A population based study of health service resource use. Diabetes Care. 2003;26:1176–80. [PubMed] [Google Scholar] 14. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jørgensen HV, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: Influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479–86. [PubMed] [Google Scholar] 15. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med. 1991;8:217–22. [PubMed] [Google Scholar] 16. ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000;23:1467–71. [PubMed] [Google Scholar] 17. Zammitt NN, Geddes J, Warren RE, Marioni R, Ashby JP, Frier BM. Serum angiotensin-converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: Does a relationship exist? Diabet Med. 2007;24:1449–54. [PubMed] [Google Scholar] 18. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6:197–202. [PubMed] [Google Scholar] 19. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health. 2006;9:193–8. [PubMed] [Google Scholar] 20. Allicar MP, Megas F, Houzard S, Baroux A, Thai F, Augendre-Ferrante B. Frequency and costs of hospital stays for hypoglycemia in France in 1995 [In French] Presse Med. 2000;29:657–61. [PubMed] [Google Scholar] 21. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25:2109–10. [PubMed] [Google Scholar] 22. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245–9. [PubMed] [Google Scholar] 24. Fanelli CG, Paramore DS, Hershey T, Terkamp C, Ovalle F, Craft S, et al. Impact of nocturnal hypoglycemia on ypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes. 1998;47:1920–7. [PubMed] [Google Scholar] 25. Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: An underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337–46. [PMC free article] [PubMed] [Google Scholar] 26. Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counter regulatory responses to hypoglycemia in type 2 diabetes. Diabetes. 2009;58:701–9. [PMC free article] [PubMed] [Google Scholar] 27. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care. 2010;33:428–33. [PMC free article] [PubMed] [Google Scholar] 28. Gama R, Teale JD, Marks V. Best practice No 173: Clinical and laboratory investigation of adult spontaneous hypoglycaemia. J Clin Pathol. 2003;56:641–6. [PMC free article] [PubMed] [Google Scholar] 29. Lammert M, Hammer M, Frier BM. Management of severe hypoglycemia: Cultural similarities, differences and resource consumption in three European countries. J Med Econ. 2009;12:269–80. [PubMed] [Google Scholar] 30. Matyka KA. Sweet dreams?-nocturnal hypoglycemia in children with type 1 diabetes. Pediatric Diabetes. 2002;3:74–81. [PubMed] [Google Scholar] 31. Beregszaszi M, Tubiana-Rufi N, Benali K, Noel M, Bloch J, Czernichow P. Nocturnal hypoglycemia in children and adolescents with insulindependent diabetes mellitus: Prevalence and risk factors. J Pediatr. 1997;131:27–33. [PubMed] [Google Scholar] 32. López MJ, Oyarzabal M, Barrio R, Hermoso F, López JP, Rodriguez M, et al. Nocturnal hypoglycaemia in IDDM patients younger than 18 years. Diabet Med. 1997;14:772–7. [PubMed] [Google Scholar] 33. Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, et al. Diabetes Research in children network direcnet study group: Impact of exercise on overnight glycemic control in Children with type 1 diabetes mellitus. J Pediatr. 2005;147:528–34. [PMC free article] [PubMed] [Google Scholar] 34. Koltin D, Daneman D. Dead-in-bed syndrome – A diabetes nightmare. Pediatr Diabetes. 2008;9:504–7. [PubMed] [Google Scholar] 35. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(Suppl 12):S134–45. [PubMed] [Google Scholar] 36. Amiel SA. Hypoglycemia avoidance, technology and knowledge. Lancet. 1998;352:502–3. [PubMed] [Google Scholar] 37. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: Reduced awakening from sleep during hypoglycemia. Diabetes. 2003;52:1195–203. [PubMed] [Google Scholar] 38. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care. 1993;16(Suppl 3):S71–89. [PubMed] [Google Scholar] 39. Towler DA, Havlin CE, Craft S, Cryer PE. Mechanism of awareness of hypoglycemia: Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42:1791–8. [PubMed] [Google Scholar] 40. Lacherade JC, Jacqueminet S, Preiser JC. An overview of hypoglycemia in the critically ill. J Diabetes Sci Technol. 2009;3:1242–9. [PMC free article] [PubMed] [Google Scholar] 41. Choudhary P, Amiel SA. Hypoglycemia: Current management and controversies. Postgrad Med J. 2011;87:298–306. [PubMed] [Google Scholar] 42. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11:17. [PMC free article] [PubMed] [Google Scholar] 43. Kalra S. Geriatric diabetes. J Pak Med Assoc. 2013;63:403–5. [PubMed] [Google Scholar] 44. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycemia in people with diabetes. Diabet Med. 2001;18:690–705. a. [PubMed] [Google Scholar] 45. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycemia in insulin-treated Type 2 diabetes: Frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016–21. [PubMed] [Google Scholar] 46. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697–703. [PubMed] [Google Scholar] 47. Asvold BO, Sand T, Hestad K, Bjørgaas MR. Cognitive function in type 1diabetic adults with early exposure to severe hypoglycemia: A 16-year follow-up study. Diabetes Care. 2010;33:1945–7. [PMC free article] [PubMed] [Google Scholar] 48. Chugani HT. A critical period of brain development: Studies of cerebral glucose utilization with PET. Prev Med. 1998;27:184–8. [PubMed] [Google Scholar] 49. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72. [PMC free article] [PubMed] [Google Scholar] 50. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117:868–70. [PMC free article] [PubMed] [Google Scholar] 51. Berz JP, Orlander JD. Prolonged cerebellar ataxia: An unusual complication of Hypoglycemia. J Gen Intern Med. 2007;23:103–5. [PMC free article] [PubMed] [Google Scholar] 52. Auer R, Hugh J, Cosgrove E, Curry B. Neuropathologic findings in three cases of profound hypoglycemia. Clin Neuropathol. 1989;8:63–8. [PubMed] [Google Scholar] 53. Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab. 2009;297:E194–201. [PMC free article] [PubMed] [Google Scholar] 54. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 124 years. Diabetes Care. 1999;22:233–40. [PubMed] [Google Scholar] 55. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(Suppl 8A):6S–11. [PubMed] [Google Scholar] 56. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986;123:504–16. [PubMed] [Google Scholar] 57. Wright RJ, Frier BM. Vascular disease and diabetes: Is hypoglycemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353–63. [PubMed] [Google Scholar] 58. Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM. Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab. 2007;293:e1274–9. [PubMed] [Google Scholar] 59. O’Rourke MF, Gallagher DE. Pulse wave analysis. J Hypertens. 1996;14:S147–57. [PubMed] [Google Scholar] 60. O’Rourke MF. Wave travel and reflection in the arterial system. J Hypertens. 1999;17:S45–7. [PubMed] [Google Scholar] 61. Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, et al. Altered ventricular repolarization during hypoglycemia in patients with diabetes. Diabet Med. 1997;14:648–54. [PubMed] [Google Scholar] 62. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34:S132–7. [PMC free article] [PubMed] [Google Scholar] 63. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003;52:1469–74. [PubMed] [Google Scholar] 64. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991;8:49–58. [PubMed] [Google Scholar] 65. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: Implications for rigorous glycemic control. Diabetes. 2009;58:360–6. [PMC free article] [PubMed] [Google Scholar] 66. Vlcek M, Radikova Z, Penesova A, Kvetnansky R, Imrich R. Heart rate variability and catecholamines during hypoglycemia and orthostasis. Auton Neurosci. 2008;143:53–7. [PubMed] [Google Scholar] 67. Kamijo Y, Soma K, Aoyama N, Fukuda M, Ohwada T. Myocardial infarction with acute insulin poisoning-A case report. Angiology. 2000;51:689–93. [PubMed] [Google Scholar] 68. Galizia AC, Fava S, Foale R. Nesidioblastosis-associated hypoglycemia presenting with prominent cardiac manifestations. Postgrad Med J. 1996;72:231–2. [PMC free article] [PubMed] [Google Scholar] 69. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33:1389–94. [PMC free article] [PubMed] [Google Scholar] 70. Razavi Nematollahi L, Kitabchi AE, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009;58:443–8. [PubMed] [Google Scholar] 71. Del Rey A, Roggero E, Randolf A, Mahuad C, McCann S, Rettori V, et al. IL-1 resets glucose homeostasis at central levels. Proc Natl Acad Sci U S A. 2006;103:16039–44. [PMC free article] [PubMed] [Google Scholar] 72. Fisher BM, Hepburn DA, Smith JG, Frier BM. Responses of peripheral blood cells to acute insulin-induced hypoglycemia in humans: Effect of alpha-adrenergic blockade. Horm Metab Res Suppl. 1992;26:109–10. [PubMed] [Google Scholar] 73. Macaluso C, Onoe S, Niemeyer G. Changes in glucose level affect rod function more than cone function in the isolated, perfused cat eye. Invest Ophthalmol Vis Sci. 1992;33:2798–808. [PubMed] [Google Scholar] 74. Luo X, Lambrou GN, Sahel JA, Hicks D. Hypoglycemia induces general neuronal death, whereas hypoxia and glutamate transport blockade lead to selective retinal ganglion cell death in vitro. Invest Ophthalmol Vis Sci. 2001;42:2695–705. [PubMed] [Google Scholar] 75. Emery M, Schorderet DF, Roduit R. Acute hypoglycemia induces retinal cell death in mouse. PLoS One. 2011;6:e21586. [PMC free article] [PubMed] [Google Scholar] 76. Umino Y, Everhart D, Solessio E, Cusato K, Pan JC, Nguyen TH, et al. Hypoglycemia leads to age-related loss of vision. Proc Natl Acad Sci U S A. 2006;103:19541–5. [PMC free article] [PubMed] [Google Scholar] 77. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12:44–52. [PMC free article] [PubMed] [Google Scholar] 78. Khan MI, Barlow RB, Weinstock RS. Acute hypoglycemia decreases central retinal function in the human eye. Vision Res. 2011;51:1623–6. [PMC free article] [PubMed] [Google Scholar] 79. Wredling RA, Theorell PG, Roll HM, Lins PE, Adamson UK. Psychosocial state of patients with IDDM prone to recurrent episodes of severe hypoglycemia. Diabetes Care. 1992;15:518–21. [PubMed] [Google Scholar] 80. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract. 2004;65(Suppl 1):S47–52. [PubMed] [Google Scholar] 81. Alvarez-Guisasola F, Yin DD, Nocea G, Qiu Y, Mavros P. Association of hypoglycemic symptoms with patients′ rating of their health-related quality of life state: A cross sectional study. Health Qual Life Outcomes. 2010;8:86. [PMC free article] [PubMed] [Google Scholar] 82. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: Lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8. [PMC free article] [PubMed] [Google Scholar] 83. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;91:363–70. [PubMed] [Google Scholar] 84. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes. 2011;4:251. [PMC free article] [PubMed] [Google Scholar] 85. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Julian DM, Clarke WL. Progressive hypoglycemia's impact on driving simulation performance.Occurrence, awareness and correction. Diabetes care. 2000;23:163–70. [PubMed] [Google Scholar] 86. Cox DJ, Kovatchev BP, Anderson SM, Clarke WL, Gonder-Frederick LA. Type 1 diabetic drivers with and without a history of recurrent hypoglycemia-related driving mishaps: Physiological and performance differences during euglycemia and the induction of hypoglycemia. Diabetes Care. 2010;33:2430–5. [PMC free article] [PubMed] [Google Scholar] 87. Deary IJ. Symptoms of Hypoglycemia and Effects on Mental Performance and Emotions. In: Frier BM, editor. Hypoglycemia in Clinical Diabetes. West Sussex, England: John Wiley and Sons, Ltd; 2007. pp. 25–48. [Google Scholar] 88. McAulay V, Deary IJ, Ferguson SC, Frier BM. Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved. Diabetes Care. 2001;24:1745–50. b. [PubMed] [Google Scholar] 89. Warren RE, Allen KV, Sommerfield AJ, Deary IJ, Frier BM. Acute hypoglycemia impairs nonverbal intelligence: Importance of avoiding ceiling Hypoglycemia and effects in cognitive function testing. Diabetes Care. 2004;27:1447–8. [PubMed] [Google Scholar] 90. Anderson BJ, Rubin RR. Practical Psychology for Diabetes Clinicians. Am Diabetes Assoc. 2002:212–24. [Google Scholar] 92. At a Glance Guide to the Current Medical Standards of Fitness to Drive: Driving and Vehicle Licensing Agency U.K. [Last accessed on 2013 May 23]. Available from: http://www.dft.gov.uk/dvla/medical/aag.aspx . 93. Jones TW, Porter P, Sherwin RS, Davis EA, O’Leary P, Frazer F, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998;338:1657–62. [PubMed] [Google Scholar] 94. Hirsch IB, Heller SR, Cryer PE. Increased symptoms of hypoglycemia in the standing position in insulin-dependent diabetes mellitus. Clin Sci (Lond) 1991;80:583–6. [PubMed] [Google Scholar] 95. Jauch-Chara K, Schultes B. Sleep and the response to hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2010;24:801–15. [PubMed] [Google Scholar] 96. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: A case for increased vigilance. Postgrad Med. 2011;124:81–91. a. [PubMed] [Google Scholar] 97. Unger J, Parkin C. Recognition, prevention, and proactive management of hypoglycemia in patients with type 1 diabetes mellitus. Postgrad Med. 2011b;123:71–80. b. [PubMed] [Google Scholar] 98. Santiago JV. Nocturnal hypoglycemia in children with diabetes: An important problem revisited. J Pediatr. 1997;131:2–4. [PubMed] [Google Scholar] 99. Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM. Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care. 2005;28:1333–8. [PubMed] [Google Scholar] 100. Lee SM, Koh D, Chui WK, Sum CF. Diabetes management and hypoglycemia in safety sensitive jobs. Saf Health Work. 2011;2:9–16. [PMC free article] [PubMed] [Google Scholar] 101. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665–71. [PubMed] [Google Scholar] 102. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: Results from a four-country survey. J Med Econ. 2012;15:77–86. [PubMed] [Google Scholar] 103. Younk LM, Mikeladze M, Tate D, Davis SN. Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab. 2011;6:93–108. [PMC free article] [PubMed] [Google Scholar] 104. Riddell MC, Perkins BA. Type 1 Diabetes and vigorous exercise: Applications of exercise physiology to patient management. Can J Diabetes. 2006;30:63–71. [Google Scholar] 105. Graveling AJ, Frier BM. Risks of marathon running and hypoglycemia in Type 1 diabetes. Diabet Med. 2010;27:585–8. [PubMed] [Google Scholar] 106. Lumb AN, Gallen IW. Diabetes management for intense exercise. Curr Opin Endocrinol Diabetes Obes. 2009;16:150–5. [PubMed] [Google Scholar] 107. Tupola S, Rajantie J, Maenpaa J. Severe hypoglycaemia in children and adolescents during multiple-dose insulin therapy. Diabet Med. 1998;15:695–9. [PubMed] [Google Scholar] 108. Frier BM. How hypoglycemia can affect the life of a person with diabete. Diabetes Metab Res Rev. 2008;24:87–92. [PubMed] [Google Scholar] 109. Cho K. Chronic ‘jet lag’ produces temporal lobe atrophy and spatial cognitive deficits. Nat Neurosci. 2001;4:567–8. [PubMed] [Google Scholar] 110. Waterhouse J, Nevill A, Edwards B, Godfrey R, Reilly T. The relationship between assessments of jet lag and some of its symptoms. Chronobiol Int. 2003;20:1061–73. [PubMed] [Google Scholar] 111. Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C VACSDM Study Group. Health related quality of life in the VA Feasibility Study on glycemic control and complications in Type 2 diabetes mellitus. J Diabetes Complications. 2005;19:207–11. [PubMed] [Google Scholar] 112. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes. 2005;29:186–92. [Google Scholar] 113. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25:245–54. [PMC free article] [PubMed] [Google Scholar] 114. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33:74–109. [PubMed] [Google Scholar] 115. Polonsky WH, Jackson RA. What's so tough about taking insulin. Addressing the problem of psychological insulin resistance in type 2 diabetes? Clin Diabetes. 2004;22:147–50. [Google Scholar] 116. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9. a. [PubMed] [Google Scholar] 117. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22:1379–85. b. [PubMed] [Google Scholar] 118. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. [Last accessed 2013 Apr 25];Diabetes Obes Metab. 2012 In press. Available from: http://www.dawnstudy.com . [PubMed] [Google Scholar] 119. Vignesh JP, Mohan V. Hypoglycaemia unawareness. J Assoc Physicians India. 2004;52:727–32. [PubMed] [Google Scholar] 120. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25:501–4. [PubMed] [Google Scholar] 121. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycaemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 1993;42:1233–7. [PubMed] [Google Scholar] 123. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–12. [PubMed] [Google Scholar] 124. Gangji AS, Gerstein HC, Cukierman T. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care. 2007;30:389–94. [PubMed] [Google Scholar] 125. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. The GUIDE study: Double blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetes. Eur J Clin Invest. 2004;34:535–42. [PubMed] [Google Scholar] 126. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50:735–41. [PubMed] [Google Scholar] 127. Shorr RI, Ray WA, Daugherty JR, Griffen MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751–5. [PubMed] [Google Scholar] 128. Boyle PJ, Zrebiec J. Impact of therapeutic advances in hypoglycemia in type 2 diabetes. Diabetes Metab Res Rev. 2008;24:257–85. [PubMed] [Google Scholar] 129. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of non-insulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410–8. [PubMed] [Google Scholar] 130. Tomky D. Detection, prevention, and treatment of hypoglycemia in the hospital. Diabetes Spectr. 2005;18:39–44. [Google Scholar] 131. Tenzer-Iglesias P, Shannon MH. Managing hypoglycemia in primary care. J Fam Pract. 2012;61(Suppl 10):S1–8. [PubMed] [Google Scholar] 132. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–64. [PubMed] [Google Scholar] 133. Unger J. Insulin initiation and intensification in patients with type 2 diabetes mellitus for the primary care physician. Diabetes Metab Syndr Obes. 2011;4:253–61. a. [PMC free article] [PubMed] [Google Scholar] 134. Unger J, Parkin C. Recognition, prevention, and proactive management of hypoglycemia in patients with type 1 diabetes mellitus. Postgrad Med. 2011;123:71–80. b. [PubMed] [Google Scholar] 135. Klonoff DC. Noninvasive blood glucose monitoring. Diabetes Care. 1997;20:433–7. [PubMed] [Google Scholar] 136. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76. [PubMed] [Google Scholar] 137. Brunton S. Safety and effectiveness of modern insulin therapy: The value of insulin analogs. Consultant. 2009;(Suppl):S13–9. [Google Scholar] 138. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64:1415–34. [PMC free article] [PubMed] [Google Scholar] 139. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycaemia risk with insulin glargine. Diabetes Care. 2005;28:950–5. [PubMed] [Google Scholar] 140. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–81. [PubMed] [Google Scholar] 141. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–74. [PubMed] [Google Scholar] 142. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice daily pre-mixed insulin as initial therapy for type 2 diabetes. Diabetes Care. 2005;28:254–9. [PubMed] [Google Scholar] 143. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. for the 4-T study group. Three year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47. [PubMed] [Google Scholar] 144. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. Randomized addition of glargine or human NPH insulin oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6. [PubMed] [Google Scholar] 145. Bretzel RG, Nuber U, Landraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet. 2008;371:1073–84. [PubMed] [Google Scholar] 146. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363–8. [PubMed] [Google Scholar] 147. Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: A double-blind, randomized, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21:769–75. [PubMed] [Google Scholar] 148. Fritsche A, Larbig M, Owens D, Häring HU GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010;12:115–23. [PubMed] [Google Scholar] 149. Realsen JM, Chase HP. Recent advances in the prevention of hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011;13:1177–86. [PubMed] [Google Scholar] 150. Lasserson DS, Glasziou P, Perera R. Optimal insulin regimens in type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetologia. 2009;52:1990–2000. [PubMed] [Google Scholar] 151. Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clin Ther. 2009;31:1641–51. [PubMed] [Google Scholar] 152. London: National Institute for Health and Clinical Excellence; 2008. National Institute for Health and Clinical Excellence: Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus: Review of Technology Appraisal Guidance 151. [Google Scholar] 153. Pickup JC, Sutton AJ. Severe hypoglycemia and glycemic control in type 1 diabetes: Meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765–74. [PubMed] [Google Scholar] 154. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. LEAD-1 SU study group.Liraglutide, a once daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD 1-SU) Diabet Med. 2009;26:268–78. [PMC free article] [PubMed] [Google Scholar] 155. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5 met+su) study group. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+su): A randomised controlled trial. Diabetologia. 2009;52:2046–55. [PMC free article] [PubMed] [Google Scholar] 156. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycemic control with minimal weight gain in patients with type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting Insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153–62. [PMC free article] [PubMed] [Google Scholar] 157. Fonjallaz P, Loumaye E. Glucagon rDNA origin (GlucaGen) and recombinant LH. (no. 12 in a series of articles to promote a better understanding of the use of genetic engineering) J Biotechnol. 2000;79:185–9. [PubMed] [Google Scholar] 158. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci. 1999;88:991–5. [PubMed] [Google Scholar] 160. Carstens S, Sprehn M. Prehospital treatment of severe hypoglycemia: A comparison of intramuscular glucagon and intravenous glucose. Prehosp Disaster Med. 1998;13:44–50. [PubMed] [Google Scholar] 161. Namba M, Hanafusa T, Kono N, Tarui S. Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group. Diabetes Res Clin Pract. 1993;19:133–8. [PubMed] [Google Scholar] 162. Patrick AW, Collier A, Hepburn DA, Steedman DJ, Clarke BF, Robertson C. Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycemic coma in an accident and emergency department. Arch Emerg Med. 1990;7:73–7. [PMC free article] [PubMed] [Google Scholar] 163. Pearson T. Glucagon as a treatment of severe hypoglycemia: Safe and efficacious but underutilized. Diabetes Educ. 2008;34:128–34. [PubMed] [Google Scholar] What happens if you give a diabetic too much glucose?Glucose then goes into the urine, causing increased urination. If it isn't treated, diabetic hyperosmolar hyperglycemic state can lead to life-threatening dehydration and coma. It's very important to get medical care for it right away.
What happens to excess glucose in the bloodstream?After a meal, glucose enters the liver and levels of blood glucose rise. This excess glucose is dealt with by glycogenesis in which the liver converts glucose into glycogen for storage. The glucose that is not stored is used to produce energy by a process called glycolysis. This occurs in every cell in the body.
How much oral glucose should be administered for a suspected hypoglycemic patient?If you suspect that your patient is hypoglycemic, obtain a blood glucose level through skin puncture. A 15 g oral dose of glucose should be given to produce an increase in blood glucose of approximately 2.1 mmol/L in 20 minutes (Canadian Diabetes Association, 2013).
What concentration of dextrose should be administered to the unconscious patient with hypoglycemia?Conclusions: Dextrose 10% delivered in 5 g (50 ml) aliquots is administered in smaller doses than dextrose 50% delivered in 5 g/10 ml aliquots, resulting in lower post-treatment blood glucose levels. We therefore recommend it as the intravenous treatment of choice for adult hypoglycaemia.
|
